Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bayer Ag ADR (OP:BAYRY)

14.50 +0.18 (+1.26%)
Streaming Delayed Price Updated: 10:17 AM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bayer Ag ADR

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
OTC Markets Group Announces Quarterly Index Performance and Rebalancing
From OTC Markets
Via GlobeNewswire
News headline image
U.S. Current-Account Deficit Widens to $450 Billion Amid Trade Imbalances and Energy Imports
The United States current-account deficit expanded sharply to $450 billion in the first half of 2025, marking a renewed widening of the country's financial shortfall with the rest of the world. This... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
News headline image
History of Recursion Pharmaceuticals, Inc.: AI‑Driven Drug Discovery Beginnings (NASDAQ:RXRX)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) emerged in the 2010s as one of the pioneers in leveraging artificial intelligence (AI) and advanced data analytics to transform drug discovery and... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars ↗
Exelixis' STELLAR-303 trial shows zanzalintinib plus Tecentriq improved survival in colorectal cancer, with no new safety concerns reported. 
Via Benzinga
News headline image
Exelixis Catapults 14% On Positive Results For Next-Gen Colon Cancer Drug ↗
Shares surged Monday after the company said its next-generation cancer drug showed promise in a colon cancer study. 
Via Investor's Business Daily
News headline image
OTC Markets Group Welcomes Bayer AG to OTCQX
From OTC Markets
Via GlobeNewswire
News headline image
Bayer Profit Drops 35%, Launches Overhaul To Counter Generic Pressure ↗
Bayer Q1 profit declined to $1.45 billion, but earnings and sales topped estimates as pharma growth offset crop science headwinds and currency impacts. 
Via Benzinga
News headline image
FDA Grants Complete Approval To Bayer's Drug For Certain Type Cancer With Mutation ↗
Bayer's Vitrakvi receives full FDA approval based on solid tumor data showing sustained efficacy in NTRK fusion-positive patients. 
Via Benzinga
News headline image
Bayer Enters License Agreement With China’s Puhe BioPharma For Cancer Drug Candidate: Retail Stays Bullish ↗
Bayer’s Pharmaceuticals Division’s Head of Business Development and Licensing Juergen Eckhardt said the drug’s “highly selective targeting” of cancer cells while sparing healthy ones is “very... 
Via Stocktwits
News headline image
Bayer CEO: 2025 Will Be 'Most Difficult' Year In Turnaround Plan, Expects Improved Performance From 2026 Onwards ↗
Bayer reported Q4 adjusted EPS of $0.28, missing estimates, but sales beat forecasts. The company sees 2025 as a tough year, with growth expected from 2026. 
Via Benzinga
Topics Earnings
News headline image
Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease Study ↗
Regeneron's EYLEA HD met key goals in the Phase 3 QUASAR trial for macular edema after retinal vein occlusion, with FDA submission expected in Q1 2025. 
Via Benzinga
News headline image
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market ↗
FDA approves BridgeBio's Attruby for ATTR-CM. Phase 3 results highlight its effectiveness in reducing cardiovascular risks and improving life quality. 
Via Benzinga
News headline image
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market ↗
BridgeBio's acoramidis shows significant reductions in mortality and hospitalizations in ATTR-CM patients, with no new safety concerns in long-term studies. 
Via Benzinga
News headline image
ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
ORIC Pharmaceuticals is a stock analyst price targets currently signal double-bagger potential in. See what the excitement around this firm is all about. 
Via MarketBeat
News headline image
Bayer Seeks European Approval For Its Menopause Drug ↗
Bayer has submitted an MAA to the EMA for elinzanetant, targeting moderate to severe vasomotor symptoms linked to menopause. Phase 3 trials showed significant reductions in VMS and improved quality of... 
Via Benzinga
News headline image
Bayer Seeks European Approval For Third Indication For Cancer Drug Darolutamide ↗
Bayer is seeking EMA approval for darolutamide in metastatic hormone-sensitive prostate cancer, building on promising Phase III ARANOTE trial results. The treatment significantly lowers progression... 
Via Benzinga
News headline image
Week In Review: Zenas Raises $259 Million In IPO ↗
It was a quiet week for biotech news in the Chinese market. Here is a brief overview of the notable events that occurred during this time. Zenas BioPharma staged a rare US biopharma IPO worth $259... 
Via Talk Markets
Topics Initial Public Offering
News headline image
Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea ↗
Eylea is one of Regeneron's biggest moneymakers, and Amgen is looking to knock it off. 
Via Investor's Business Daily
“Signing Day Sports, Inc. (NYSE American: SGN) Soars in Pre-Market on Acquisition News – see more penny stocks inside….”
Via AB Newswire
News headline image
Bayer Targets Expanded Use Approval For Prostate Cancer Drug, Reveals Encouraging Data From Pivotal Study ↗
Bayer's Phase 3 ARANOTE trial showed darolutamide plus androgen deprivation therapy (ADT) reduced the risk of radiological progression or death in metastatic hormone-sensitive prostate cancer patients... 
Via Benzinga
News headline image
Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer ↗
Roivant Sciences has licensed worldwide rights to develop and commercialize Bayer's mosliciguat for an upfront payment of $14 million and up to $280 million in future milestone payments. 
Via Benzinga
News headline image
Why Is BridgeBio Pharma Stock Trading Higher On Friday? ↗
BridgeBio Pharma presented additional data from its Phase 3 ATTRibute-CM study of acoramidis in ATTR-CM at the European Society of Cardiology 2024, showing increased serum TTR levels in participants... 
Via Benzinga
News headline image
BAYRY Stock Earnings: Bayer Meets EPS, Beats Revenue for Q2 2024 ↗
BAYRY stock results show that Bayer met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Bayer Weedkiller Lawsuit Dismissed By Australian Judge: Insufficient Evidence Linking Roundup To Blood Cancer ↗
Australian judge dismisses class action lawsuit against Bayer for Roundup causing cancer. Ruling supports company's stance that product is safe. 
Via Benzinga
Topics Lawsuit
News headline image
ScottsMiracle-Gro Stock Blooms After Investor Day Optimism
Lawn and garden products manufacturer ScottsMiracle-Gro Co. (NYSE: SMG) stock surged on its Investor Day update ahead of fiscal Q3 2024 earnings release. 
Via MarketBeat
Topics Cannabis
News headline image
3 Longevity Stocks to Buy for Anti-Aging Breakthroughs ↗
Longevity stocks are at the forefront of combating age-related illnesses with transformative AI-driven drug discovery. 
Via InvestorPlace
News headline image
3 Small-Cap Stocks With Explosive 2X Growth Potential ↗
Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024. 
Via InvestorPlace
News headline image
Judge Slashes Bayer's Massive $2B Roundup Verdict To $400M ↗
Pennsylvania judge cuts Bayer's $2.25 billion Roundup verdict to $400 million. Both Bayer and plaintiff plan appeals in the ongoing cancer litigation. 
Via Benzinga
News headline image
Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership ↗
Suzhou MediLink partnered with Germany’s BioNTech to use MediLink’s TMALIN antibody-drug conjugate platform. MediLink will receive an upfront payment of $25 million and up to $1.8 billion in... 
Via Talk Markets
News headline image
European Equities Close Higher As Traders Bank On Imminent ECB Rate Cut: What's Driving Markets Monday? ↗
European equities up, ECB likely to cut rates in June, traders confident. Euro slightly higher. Top performers: RWE, Bayer, VW, Enel, Iberdrola. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.